๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for HR+/HER2- Breast Cancer

SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer NCT06340230Phase 21 site๐Ÿ“ Shenyang Shengjing Hospital ยท Tests: SHR-A1811 Injection + Adebrelimab Injection, SHR-A1811 Injection + Adebrelimab Injection, SHR-A1811 Injection ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness NCT07084558NA14 sites๐Ÿ“ Vienna๐Ÿ“ Baden๐Ÿ“ Dornbirn Austrian Breast & Colorectal Cancer Study Group ยท Tests: blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived) A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer NCT06678269Phase 17 sites๐Ÿ“ Basking Ridge๐Ÿ“ Middletown๐Ÿ“ Montvale Memorial Sloan Kettering Cancer Center ยท Tests: Abemaciclib, Radiation Therapy Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks NCT05212454Phase 31 site๐Ÿ“ Hanzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: Capecitabine A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors NCT07318805Phase 113 sites๐Ÿ“ Duarte๐Ÿ“ Grand Rapids๐Ÿ“ Long Island City Pfizer ยท Tests: PF-08032562, Fulvestrant, Cetuximab, Fluorouracil, Oxaliplatin A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer NCT07678957Phase 21 site๐Ÿ“ Beijing Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-M07D1, DS-8201 Study of AVZO-021 in Patients With Advanced Solid Tumors NCT05867251Phase 1, Phase 213 sites๐Ÿ“ New Haven๐Ÿ“ Sarasota๐Ÿ“ Tampa Avenzo Therapeutics, Inc. ยท Tests: AVZO-021, Palbociclib, Fulvestrant, Letrozole, Ribociclib HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan NCT06236269Phase 210 sites๐Ÿ“ Badalona๐Ÿ“ L'Hospitalet de Llobregat๐Ÿ“ Barcelona SOLTI Breast Cancer Research Group ยท Tests: Sacituzumab Govitecan A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Guangzhou Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ยท Tests: SKB264, Nab-paclitaxel, Paclitaxel, Capecitabine Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer NCT05306041Phase 262 sites๐Ÿ“ Essen๐Ÿ“ Augsburg๐Ÿ“ Berlin GBG Forschungs GmbH ยท Tests: Inavolisib, PHESGO, Endocrine therapy Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC. NCT06705127Phase 21 site๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: TORIPALIMAB INJECTION(JS001 ), Stereotactic Body Radiation Therapy (SBRT) Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer NCT05524584Phase 21 site๐Ÿ“ Orange University of California, Irvine ยท Tests: Fulvestrant, Anastrozole, Abemaciclib A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) NCT07648914Phase 31 site๐Ÿ“ Beijing Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: BL-B01D1, Albumin-Bound Paclitaxel, Paclitaxel, Capecitabine Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy NCT07137871Phase 11 site๐Ÿ“ San Antonio The University of Texas Health Science Center at San Antonio ยท Tests: Avasopasem Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors NCT07288359Phase 1, Phase 216 sites๐Ÿ“ Atlanta๐Ÿ“ Nashville๐Ÿ“ San Antonio Novartis Pharmaceuticals ยท Tests: GVV858, Fulvestrant, Letrozole A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer NCT07358377Phase 16 sites๐Ÿ“ Bowral๐Ÿ“ Sydney๐Ÿ“ Sydney Atridia Pty Ltd. ยท Tests: HRS-6209 Capsules and fulvestrant injection Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast Cancer NCT05949541Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: Everolimus 10 mg, CDK4/6 Inhibitor SHR6390, Aromatase inhibitor and Fulvestrant combined with CDK4/6 inhibitors Dalpiciclib Plus Toremifene for First-line Advanced HR Positive and HER2 Negative Breast Cancer NCT06495515Phase 21 site๐Ÿ“ Tianjin Tianjin Medical University Cancer Institute and Hospital ยท Tests: Dalpiciclib๏ผŒToremifen Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib NCT07237256Phase 3138 sites๐Ÿ“ Amiens๐Ÿ“ Angers๐Ÿ“ Argenteuil UNICANCER ยท Tests: Chemotherapy followed by endocrine therapy and ribociclib treatment, De-escalation Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors NCT05969041Phase 16 sites๐Ÿ“ Darlinghurst๐Ÿ“ Randwick๐Ÿ“ Westmead Myeloid Therapeutics ยท Tests: MT-302 (A) CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS) NCT07019363Phase 31 site๐Ÿ“ Shanghai Fudan University ยท Tests: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Standard endocrine therapy combined with CDK4/6 Inhibโ€ฆ Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer NCT07531693n/a1 site๐Ÿ“ Erlangen Institut fuer Frauengesundheit Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer NCT05878314n/a1 site๐Ÿ“ Tรผbingen University Hospital Tuebingen RADIANT: Pre-op Radiation With Abemaciclib and Letrozole NCT06139107Phase 14 sites๐Ÿ“ Belleville๐Ÿ“ Livingston๐Ÿ“ New Brunswick Mridula George, MD ยท Tests: Abemaciclib, Letrozole Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC. NCT06033287n/a1 site๐Ÿ“ Changsha Hunan Cancer Hospital ยท Tests: Different treatment regimens following progression on CDK4/6 inhibitors. Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment NCT07553234NA1 site๐Ÿ“ Chicago University of Chicago ยท Tests: Stool Sampling, Chia Seeds Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study NCT06805812n/a24 sites๐Ÿ“ Aviano๐Ÿ“ Brescia๐Ÿ“ Catania Fondazione IRCCS Istituto Nazionale dei Tumori, Milano ยท Tests: Palbociclib, Ribociclib, Abemaciclib A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. NCT07062965Phase 3433 sites๐Ÿ“ Anchorage๐Ÿ“ Chandler๐Ÿ“ Gilbert Pfizer ยท Tests: PF-07248144, Fulvestrant, Everolimus, Exemestane Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer NCT06341894Phase 21 site๐Ÿ“ Nanjing The First Affiliated Hospital with Nanjing Medical Universiโ€ฆ ยท Tests: Dalpiciclib, Endocrine therapy Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer NCT06774027n/a3 sites๐Ÿ“ San Francisco๐Ÿ“ The Bronx๐Ÿ“ Durham University of California, San Francisco ยท Tests: Specimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Medical Record Review
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy